Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CDC42 | P60953 | 1/20 | 0.48 |
| ▸ | RAC1 | P63000 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6936252 | 0.88 | METAP1 (0.43) | PTGS2AKR1C3AKR1C2PTGS1CYP1A2 | |
| SCHEMBL3869414 | 0.85 | METAP1 (0.42) | TSHRMETAP1GAAALDH1A1L3MBTL1 | |
| SCHEMBL7605900 | 0.83 | AKR1C3 (0.51) | AKR1C3AKR1C2PTGS1CYP1A2METAP1 | |
| SCHEMBL11811157 | 0.83 | ALDH1A1 (0.43) | PTGS2AKR1C3AKR1C2PTGS1CYP1A2 | |
| SCHEMBL5712318 | 0.80 | PTGS2 (0.37) | PTGS2AKR1C3AKR1C2PTGS1CYP1A2 | |
| SCHEMBL6933142 | 0.78 | AKR1C3 (0.37) | PTGS2AKR1C3AKR1C2PTGS1CYP1A2 | |
| SCHEMBL7409039 | 0.78 | FFAR1 (0.44) | AKR1C3AKR1C2PTGS1CYP1A2METAP1 | |
| SCHEMBL11847964 | 0.77 | CXCR5 (0.35) | ALDH1A1 | |
| SCHEMBL10607263 | 0.76 | HTR2C (0.42) | CYP1A2METAP1CYP2C19GAAALDH1A1 | |
| SCHEMBL8431676 | 0.76 | METAP1 (0.42) | CYP1A2METAP1CYP2C19GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435962-A4 | TREATMENT OF TYPE I DIABETES | CELL PATHWAYS INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20060252762-A1 | Methods for treatment of multiple sclerosis | WHITEHEAD CLARK M | 2006-11-09 | — | — | US | disclosed |
| US-20060100210-A1 | Methods for treatment of scleroderma | WHITEHEAD CLARK M | 2006-05-11 | — | — | US | disclosed |
| US-6906064-B2 | Method for treating a patient with neoplasia using Iressa | OSI PHARMACEUTICALS, INC. | 2005-06-14 | — | — | US | disclosed |
| EP-1435961-A4 | TREATMENT FOR LUPUS ERYTHEMATOSUS | CELL PATHWAYS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1435940-A4 | TREATMENT OF SCLERODERMA | CELL PATHWAYS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1435962-A2 | TREATMENT OF TYPE I DIABETES | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435940-A1 | TREATMENT OF SCLERODERMA | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435961-A2 | TREATMENT FOR LUPUS ERYTHEMATOSUS | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435782-A1 | TREATMENT FOR CYSTIC FIBROSIS | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6166053-A | Substituted condensation products of N-benzyl-3-idenylacetamides with heterocyclic aldehydes for neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-1044187-A1 | N-BENZYL-3-INDENYLACETAMIDES DERIVATIVES FOR TREATING NEOPLASIA | OSI Pharmaceuticals, Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| US-6066634-A | PHOSPHODIESTERASE INHIBITOR | CELL PATHWAYS, INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-5948779-A | APOPTOSIS; ANTICANCER AGENT | CELL PATHWAYS, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1999031065-A1 | N-BENZYL-3-INDENYLACETAMIDES DERIVATIVES FOR TREATING NEOPLASIA | CELL PATHWAYS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5776962-A | Lactone compounds for treating patient with precancerous lesions | CELL PATHWAYS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5696159-A | Lactone compounds for treating patients with precancerous lesions | CELL PATHWAYS, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| EP-0723442-A4 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS INC (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0723442-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996003987-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100210-A1 | Methods for treatment of scleroderma | SSB, TST, ETF1 | PTGS2 449/4885AKR1C3 971/4885AKR1C2 1513/4885 |
| US-20060252762-A1 | Methods for treatment of multiple sclerosis | MYT1, PMP22, OTC | PTGS2 538/4885AKR1C3 938/4885AKR1C2 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.